Skip to main content

Posts tagged with "Current Events"

  • Covid-19

    Taking Hydroxychloroquine (May 19 Update)

    I was not planning to revisit this topic just yet, but President Trump has forced the issue with his mention yesterday that he’s taking hydroxychloroquine. Let’s try to keep this short: does any regular reader here actually wonder what I might think about that? I know that the comments section here gets swarmed with people… Read More
  • Covid-19

    More Chinese Traditional Medicine, Unfortunately

    I mentioned the other day that what was reported as a hydroxychloroquine trial in China may well have been (or at least begun as) a trial of “traditional Chinese medicine” (TCM). It doesn’t take much digging to turn up a number of registered clinical trials for coronavirus therapy via TCM, actually. Here are a few… Read More
  • Clinical Trials

    About Remdesivir and About “Game-Changers”

    We’ve had several releases of remdesivir data, and this was not exactly one of those controlled-release formulations. No, this was more in the “chaotic mess” category, with news items coming from several sources with partial information. I decided not to blog on it until the loud banging noises stopped, and I’m glad I did, s… Read More
  • Covid-19

    Monoclonal Antibodies for the Coronavirus (Updated May 5th)

    Antibodies as a therapy Let’s have a look at what is (in my opinion) probably our best shot at a reasonably short-term targeted therapy against the COVID-19 epidemic: the possibility of using monoclonal antibodies. These can be developed more quickly than vaccines, and a lot more quickly than a new targeted small-molecule antiviral. Like ever… Read More
  • Clinical Trials

    Anti IL-6 For Coronavirus Patients: Does It Work, or Not?

    It’s been looking for some time as if these coronavirus infections need a biphasic approach to therapy – an antiviral approach earlier on, and for those in serious trouble, perhaps a shift to immune modulation as the body’s reaction to the virus starts doing even more harm. That post goes into some detail on possible… Read More
  • Covid-19

    A Close Look at the Frontrunning Coronavirus Vaccines As of May 1 (updated)

    There’s plenty of news on the coronavirus vaccine front, so let’s have a look. If you need some details on the different sorts of vaccines in general, here’s the background post, which should help this one make sense. This is a rapidly advancing field, with a huge number of programs. Some of the players are… Read More
  • Current Events

    The Politics of Hydroxychloroquine

    I had not been planning to return to the topic of hydroxychloroquine so soon, but here we are. This will not be a calm, measured blog post – fair warning. Yesterday, Dr. Rick Bright was pushed out of his post at HHS, where he was deputy assistant secretary for preparedness and response and director of BARDA… Read More
  • Biological News

    Watching For Mutations in the Coronavirus

    The coronavirus outbreak has been accompanied by a huge amount of sequencing data, as well it should be. is a great place to see this in action: region by region, the spread of the infection can be tracked, often with enough detail to say where the virus must have come in from and how… Read More
  • Clinical Trials

    What’s Happening With Remdesivir?

    Well, everyone was just dealing with the news that Gilead’s antiviral remdesivir had had two trials suspended in China, when Stat‘s Adam Feuerstein and Matthew Herper broke news last night about a trial here in the US. 125 patients had been recruited at the University of Chicago to receive daily doses of remdesivir, and the… Read More
  • Clinical Trials

    Coronavirus Vaccine Prospects

    Time for another look at the coronavirus vaccine front, since we have several recent news items. Word has come from GSK and Sanofi that they are going to collaborate on vaccine development, which brings together two of the more experienced large organizations in the field. It looks like Sanofi is bringing the spike protein and… Read More